Adamas Pharmaceuticals, a privately owned manufacturer based in California, announced two executive appointments: Michael Coffee, SVP, sales and marketing, and Amy Patrick, VP, research. Coffee was previously chief business officer for Avigen, president and chief operating officer at Amarin Pharmaceuticals, and president and COO at Elan Pharmaceuticals, among other postions. Patrick began her career at Bristol-Myers Squibb, before joining Agouron Pharmaceuticals. Most recently, she was VP, biological sciences at Genelabs Technologies.
McCann Healthcare Worldwide announced a reorganization of its medical communications divisions, including the promotion of Charlie Buckwell to worldwide head of Medical Communications, a group now comprised of McCann's Complete Medical Group and Caudex Medical. Additionally, Phill Sutcliff was promoted from CFO of Complete Medical Group and Caudex Medical to CFO global medical communications and healthcare for Europe, the Middle East and Africa. Buckwell was previously chief executive of Complete Medical Group.
Newton, MA-based Pro-Pharmaceuticals, a developer of carbohydrate-based targeted therapeutic compounds for cancer and fibrosis, announced the appointment of Arthur “Bobby” Greenberg to its board of directors. Pro-Pharmaceuticals' lead product candidate is Davanat, a treatment for colorectal cancer, currently in phase 2 of development.